TY - JOUR T1 - Cardiopulmonary Arrest After Severe Anaphylactic Reaction to Second Infusion of Infliximab in a Patient with Ankylosing Spondylitis JF - The Journal of Rheumatology JO - J Rheumatol SP - 1220 LP - 1220 DO - 10.3899/jrheum.110076 VL - 38 IS - 6 AU - HARUKA MIKI AU - AKIKO OKAMOTO AU - KAZUYOSHI ISHIGAKI AU - OH SASAKI AU - SHUJI SUMITOMO AU - KEISHI FUJIO AU - KAZUHIKO YAMAMOTO Y1 - 2011/06/01 UR - http://www.jrheum.org/content/38/6/1220.abstract N2 - To the Editor:Infliximab is an anti-tumor necrosis factor-α (TNF-α) chimeric monoclonal antibody widely used to treat chronic inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis (AS), and psoriasis. Infusion reaction to infliximab occurs in approximately 5% of patients1. Although severe anaphylactic reactions including hypotension, arrhythmia, and bronchospasm have been reported, there is no report of cardiopulmonary arrest strongly connected with the infliximab infusion. We describe a patient with AS who developed cardiopulmonary arrest after an anaphylactic reaction to the second infliximab infusion.A 37-year-old man with no history of allergy or coronary artery event received infliximab infusion for AS at our hospital. His symptoms were refractory to nonsteroidal antiinflammatory drugs, and he had been treated with … Address correspondence to Dr. Fujio; E-mail: kfujio-tky{at}umin.ac.jp ER -